Market Overview

Stocks Hitting 52-Week Highs

Share:
Related MDVN
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1
Barclays Analyst Sees Biotech FY15 EPS Growth Outstripping Market
Valeant Agrees To Buy Dendreon's Provenge (Investor's Business Daily)
Related TEVA
Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's Generic Nexium
Benzinga's Weekend M&A Chatter
Teva Gains FDA Nod for Generic of AstraZeneca's Nexium - Analyst Blog (Zacks)

Medivation (NASDAQ: MDVN) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00.

Teva Pharmaceutical Industries (NYSE: TEVA) shares reached a new 52-week high of $45.60 after the company reported the FDA approval of three-times-a-week COPAXONE 40mg/mL.

CBRE Group (NYSE: CBG) shares jumped 1.54% to touch a new 52-week high of $27.06. CBRE Group is expected release its Q4 financial results on February 5, 2014.

Jones Lang LaSalle (NYSE: JLL) shares surged 5.69% to reach a new 52-week high of $112.36 after the company reported stronger-than-expected Q4 results.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

 

Related Articles (CBG + JLL)

Around the Web, We're Loving...

Get Benzinga's Newsletters